177 related articles for article (PubMed ID: 25221647)
21. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
22. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
Liu J; Xing Y; Rong L
Oncol Rep; 2018 Apr; 39(4):1631-1639. PubMed ID: 29484437
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway.
Mi S; Xiang G; Yuwen D; Gao J; Guo W; Wu X; Wu X; Sun Y; Su Y; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2016 Nov; 310():78-86. PubMed ID: 27639426
[TBL] [Abstract][Full Text] [Related]
25. NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation.
Sun Z; Li Q; Zhang S; Chen J; Huang L; Ren J; Chang Y; Liang Y; Wu G
Onco Targets Ther; 2015; 8():269-77. PubMed ID: 25674002
[TBL] [Abstract][Full Text] [Related]
26. Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma
Yu CC; Hung SK; Lin HY; Chiou WY; Lee MS; Liao HF; Huang HB; Ho HC; Su YC
Oncotarget; 2017 Sep; 8(40):68641-68653. PubMed ID: 28978144
[TBL] [Abstract][Full Text] [Related]
27. NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma.
Huang JC; Cui ZF; Chen SM; Yang LJ; Lian HK; Liu B; Su ZH; Liu JS; Wang M; Hu ZB; Ouyang JY; Li QC; Lu H
Oncotarget; 2018 Feb; 9(12):10483-10496. PubMed ID: 29535821
[TBL] [Abstract][Full Text] [Related]
28. Synergistic killing of lung cancer cells by cisplatin and radiation via autophagy and apoptosis.
Liu M; Ma S; Liu M; Hou Y; Liang B; Su X; Liu X
Oncol Lett; 2014 Jun; 7(6):1903-1910. PubMed ID: 24932256
[TBL] [Abstract][Full Text] [Related]
29. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
30. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.
Moon du G; Lee SE; Oh MM; Lee SC; Jeong SJ; Hong SK; Yoon CY; Byun SS; Park HS; Cheon J
Int J Oncol; 2014 Sep; 45(3):1027-35. PubMed ID: 24969552
[TBL] [Abstract][Full Text] [Related]
31. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
32. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
[TBL] [Abstract][Full Text] [Related]
33. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways.
Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
Cell Death Dis; 2014 Oct; 5(10):e1437. PubMed ID: 25275598
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway.
Liu F; Gao S; Yang Y; Zhao X; Fan Y; Ma W; Yang D; Yang A; Yu Y
Oncol Rep; 2018 Mar; 39(3):1523-1531. PubMed ID: 29328421
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
36. Effect of BRAF-mediated PI3K/Akt/mTOR pathway on biological characteristics and chemosensitivity of NSCLC A549/DDP cells.
Ren B; Liu H; Yang Y; Lian Y
Oncol Lett; 2021 Aug; 22(2):584. PubMed ID: 34122635
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK
Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
39. Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer.
Kim KW; Hwang M; Moretti L; Jaboin JJ; Cha YI; Lu B
Autophagy; 2008 Jul; 4(5):659-68. PubMed ID: 18424912
[TBL] [Abstract][Full Text] [Related]
40. Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy.
Xu CX; Zhao L; Yue P; Fang G; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
Cancer Biol Ther; 2011 Sep; 12(6):549-55. PubMed ID: 21738008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
